Overview

D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This study has been designed to evaluate whether combination chemotherapy and "anti-angiogenesis" therapy with thalidomide is equal or superior to autologous transplantation for the treatment of multiple myeloma.
Phase:
Phase 3
Details
Lead Sponsor:
University of Arkansas
Collaborator:
Celgene Corporation
Treatments:
Melphalan
Thalidomide